Providers

The 1-year gap after the end of the Oncology Care Model (OCM) means some practices have to make hard decisions regarding cost of care or the financial health of the practice, explained Lalan Wilfong, MD, vice president of Payer Relations & Practice Transformation at The US Oncology Network.

Post hoc analyses of the phase 3 PEGASUS trial found that clinical and hematological improvements were associated with better patient-reported fatigue and physical function outcomes in paroxysmal nocturnal hemoglobinuria, for an overall bettering of health-related quality of life (HRQOL).

Patients with atopic dermatitis (AD) were not found to be at greater risk of venous thromboembolism, regardless of Janus kinase inhibitor use, according to this new meta-analysis.

This new study investigated risk factors for cardiovascular disease, including heart failure, among hospitalized patients with a recent history of methamphetamine use and priority patient populations to target.

Lack of state funding and understaffing are threatening the vaccination campaign for novel Omicron-specific booster shots; experts explore the differences between subcutaneous and intradermal delivery of monkeypox vaccines; HHS’ Office for Civil Rights is struggling to manage rising cases of cyberattacks on US health care organizations.

Having a biosimilar on formulary makes it more likely the biosimilar will be adopted. Length of time a biosimilar is on market can impact how likely it is to be added to formulary.

Do-it-yourself (DIY) automated insulin delivery systems have gained rapid uptake, yielding self-reported improvements in glycemic control and quality of life for patients, but creating unique challenges for health care providers (HCPs).

Brindley Brooks, who founded HS Connect (HSconnect.org), a patient advocacy group for those affected by hidradenitis suppurativa (HS), spoke on misconceptions she’s encountered on her HS disease journey and the importance for physicians to be conscientious of their advice to patients.

Beyond smoking, the environment patients live in as well as their occupational risk factors all play large roles in the development of chronic obstructive pulmonary disease (COPD).

Jason Ezra Hawkes, MD, MS, FAAD, board-certified dermatologist and associate professor of dermatology at the University of California Davis in Sacramento, explained the utility of type 2 inflammation pathways and the microbiome in understanding the immune dysregulation associated with atopic dermatitis (AD).

A case report of a patient with acne fulminans, a rare form of acne vulgaris, discussed the clinical manifestations of the disease, physical examination findings, and management strategies.

Findings from this multicenter randomized controlled trial showed that the transition bundle was associated with a lower risk of 7-day and 30-day hospital readmission from chronic obstructive pulmonary disease (COPD).

Findings of a meta-analysis show that use of dietary elimination had a minimal effect on the severity of atopic dermatitis and may increase the risk of developing immunoglobulin E–mediated food allergy.

The FDA approved the first high-concentration adalimumab biosimilar. A low-concentration version of the biosimilar, Hadlima, was already approved. Both versions will launch in July 2023.

Adequate training will help physicians and researchers better address the needs of the communities they’re targeting, explained Vivienne Hau, MD, clinical assistant professor with the Kaiser Permanente Bernard J. Tyson School of Medicine.

A new review outlines what is known about cardiovascular disease (CVD) risk in patients with systemic lupus erythematosus (SLE) and how that might affect patient care.

Patients with Parkinson disease who adhered to a healthy diet pattern and active lifestyle had a lower rate of all-cause mortality than those reporting poor diet quality and lack of physical activity.

Despite intranasal corticosteroid (INCs) being a treatment mainstay for chronic rhinosinusitis with nasal polyps, there are ongoing high rates of nonadherence, which can affect treatment efficacy, according to this study’s authors.

Investigator Global Assessment score of very severe atopic dermatitis (AD) was associated with dupilumab discontinuation due to adverse effects, although generally adequate 1-, 2-, and 3-year drug survival rates were also observed.

Most participants were able to complete the assessments at home, and their scores correlated well with in-clinic assessments.

Adult patients from dermatology clinics affiliated with 2 Midwest universities were evaluated for their ability to differentiate skin cancer by sight and for their skin cancer knowledge.

Patient engagement solutions facilitate active care participation, but several myths persist that hinder their adoption and implementation.

Results from DESTINY-Lung01 have shown promising progression-free survival and overall survival with ongoing research that may lead to a future FDA approval in non–small cell lung cancer (NSCLC), said Ticiana Leal, MD, associate professor, director of the Thoracic Medical Oncology Program, Department of Hematology and Medical Oncology, Emory University School of Medicine.

The Institute for Value-Based Medicine series visits Texas Oncology in Austin.